These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19297282)

  • 1. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
    Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
    J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    Patatanian L
    Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

  • 5. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis.
    Mukhopadhyay S; Baer S; Blanshard J; Coleman M; Carswell F
    J Antimicrob Chemother; 1993 Mar; 31(3):429-36. PubMed ID: 8486576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis.
    Stephens D; Garey N; Isles A; Levison H; Gold R
    Pediatr Infect Dis; 1983; 2(3):209-11. PubMed ID: 6408619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis.
    Florescu MC; Lyden E; Murphy PJ; Florescu DF; Fillaus J
    Hemodial Int; 2012 Jul; 16(3):414-9. PubMed ID: 22469183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin.
    Barry PJ; Jones AM
    J Cyst Fibros; 2014 Dec; 13(6):754. PubMed ID: 24795286
    [No Abstract]   [Full Text] [Related]  

  • 15. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.
    Crifo S; Antonelli M; Gagliardi M; Lucarelli N; Marcolini P
    Int J Pediatr Otorhinolaryngol; 1980 Sep; 2(3):251-3. PubMed ID: 6821312
    [No Abstract]   [Full Text] [Related]  

  • 16. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
    Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of cystic fibrosis--step by step.
    Hazinski TA
    J Pediatr; 2001 Oct; 139(4):3A. PubMed ID: 11598588
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Falsely elevated serum tobramycin levels in a patient receiving nebulised tobramycin.
    Struthers SL; Nicholson T; Jones G; Connett GJ
    J Cyst Fibros; 2002 Sep; 1(3):146-7. PubMed ID: 15463821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
    Prayle AP; Jain K; Touw DJ; Koch BC; Knox AJ; Watson A; Smyth AR
    J Cyst Fibros; 2016 Jul; 15(4):510-7. PubMed ID: 26282839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.